Differentiation of Early Lyme Disease from Southern Tick-Associated Rash Illness (STARI)

Opportunity

Available for Licensing

IP Status

US Utility Patent Pending: US 2020/0140915 A1 

Inventors

John T Belisle
Claudia R Molins
Gary P Wormser

At A Glance

By applying an unbiased metabolomics approach with sera retrospectively obtained from well-characterized patients, researchers at Colorado State University in collaboration with the Centers for Disease Control defined biochemical and diagnostic differences between early Lyme disease and STARI.  The novel method can distinguish between early Lyme disease and STARI with 98 percent accuracy.

Please contact our office for more information.

Licensing Directors

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  17-086

Background

Lyme disease, the most commonly reported vector-borne disease in the United States, results from infection with Borrelia burgdorferi. Early clinical diagnosis of this disease is largely based on the presence of an erythematous skin lesion for individuals in high-risk regions. This, however, can be confused with other illnesses including southern tick-associated rash illness (STARI), an illness that lacks a defined etiological agent or laboratory diagnostic test, and is co-prevalent with Lyme disease in portions of the Eastern United States.

Benefits
  • Increased sensitivity
  • High specificity
  • Early detection
  • Differentiates between Lyme disease and STARI
Publications

Differentiating Lyme Disease from STARI. National Institute of Allergy and Infectious Diseases, U.S. Department of Health and Human Services, 18 Aug. 2017, www.niaid.nih.gov/news-events/differentiating-lyme-disease-stari.

C. Molins, et al. Metabolic differentiation of early Lyme disease from southern tick–associated rash illness (STARI). Science Translational Medicine. DOI: 10.1126/scitranslmed.aal2717 (2017).

Last updated: April 2020

Add keywords or various names of inventors here (text is hidden)